This article is more than 5 years old. Information may no longer be current.
Injectable filler may treat orbital volume deficiency after enucleation
Ophthal Plast Reconstr Surg.2011;27(2):90-94.
Click Here to Manage Email Alerts
Injectable calcium hydroxylapatite showed significant utility in orbital augmentation to correct post-enucleation/evisceration socket syndrome, a study found.
The technique was shown to be a viable alternative to more invasive methods of orbital augmentation.
"With the availability to perform the procedure in an office setting, this technique offers a cost savings compared with more invasive surgery," the study authors said. "There is ease of application in which a titratable volume can be administered with the option for sequential augmentation. Patients have a rapid rehabilitation and likely retain the same prosthesis."
The retrospective study included 26 patients with post-enucleation/evisceration socket syndrome. Mean patient age was 42 years. Indications for primary enucleation or evisceration were blind painful eye, irreparable globe trauma, retinoblastoma, uveal melanoma, microphthalmos and unknown ocular tumor.
Patients underwent injections of calcium hydroxylapatite (Radiesse, Bioform Medical) for orbital volume augmentation. Orbital augmentation was performed on the right side in 73% of cases. Fifteen patients were followed up at least 6 months and were included in the analysis. Mean follow-up was 46 weeks.
Study results showed sustained clinical and aesthetic benefits in 87% of patients up to 1.5 years. The decrease in relative enophthalmos ranged from 1 mm to 4 mm per syringe of filler material. Each syringe of filler yielded a mean improvement of 2.4 mm.
Complications included one limited peribulbar hemorrhage and two cases of anterior migration of injectable calcium hydroxylapatite. All three complications were corrected, the authors reported.